People
People on the move.
Duessoldorf, Germany (June 5)–The supervisory board of named Patrik Wohlhauser, currently head of the exclusive synthesis & catalysts business unit, as an executive director of Degussa GmbH. From July 1, 2007, his new responsibilities will include, among others, the new international sales function of RAG's subsidiary Degussa. Wohlhauser will also be the management board member responsible for the Consumer Solutions reporting segment and for the Western and Eastern Europe regions. His successor as head of the exclusive synthesis & catalysts business unit will be Rudolf Hanko, who currently heads the exclusive synthesis business line of the same business unit.
San Diego, CA (June 5)– appointed Catherine J. Hardalo, MD, vice-president of clinical development. Hardalo joins the company from Schering-Plough Research Institute, where she directed the clinical development of antimicrobial products.
San Diego, CA (June 4)–Carol G. Gallagher was promoted to senior vice-president of corporate development and commercial affairs with . Gallagher joined the company as vice-president of commercial affairs in April 2006. She previously served as vice-president of sales, marketing, and product planning at CancerVax Corporation and senior director of oncology marketing at Biogen Idec, Inc.
Emeryville, CA (May 31)– named Rob Frankenberg, PhD, vice-president of drug manufacturing. Frankenberg joins the company after serving in various positions with Bayer HealthCare.
Mississauga, ON, Canada (May 29)– named Bruce DeChambre vice-president of commercial and business development. DeChambre previously was vice-president of sales and marketing at SAB-Pharma. He also held positions at Abraxis Pharmaceutical, Fujisawa USA, Inc., and Baxter Healthcare Corp.
Irvine, CA (May 29)–Timothy P. Walbert was named chief executive officer of . Walbert previously was executive vice-president, commercial operations with NeoPharm, Inc.
Indianapolis, IN (May 25)– promoted Frank Deane to president of manufacturing. Deane is currently vice-president of quality. He joined Lilly in 1979 at the company's manufacturing operations in Kinsale, Ireland.
Burlington, MA (May 24)–Robert M. Haggerty was appointed vice-president of quality with Haggerty served as director of quality assurance at Alexion Pharmaceuticals and held various positions at Ben Venue, Dupont, and Transkaryotic Therapies.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
